Literature DB >> 10543403

G130V, a common FRDA point mutation, appears to have arisen from a common founder.

M B Delatycki1, M Knight, M Koenig, M Cossée, R Williamson, S M Forrest.   

Abstract

Friedreich ataxia (FRDA) is the most common inherited ataxia. About 98% of mutant alleles have an expansion of a GAA trinucleotide repeat in intron 1 of the affected gene, FRDA. The other 2% are point mutations. Of the 17 point mutations so far described, three appear to be more common. One of these is the G130V mutation in exon 4 of FRDA. G130V, when present with an expanded GAA repeat on the other allele, is associated with an atypical FRDA phenotype. Haplotype analysis was undertaken on the four families who have been described with this mutation. The results suggest a common founder for this mutation. Although marked differences in extragenic marker haplotypes were seen in one family, similar intragenic haplotyping suggests the same mutation founder for this family with the differences explicable by two recombination events.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543403     DOI: 10.1007/s004399900142

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  13 in total

1.  A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype.

Authors:  Marguerite V Evans-Galea; Louise A Corben; Justin Hasell; Charles A Galea; Michael C Fahey; Desirée du Sart; Martin B Delatycki
Journal:  Neurogenetics       Date:  2011-08-10       Impact factor: 2.660

2.  Developing an objective evaluating system to quantify the degree of upper limb movement impairment in patients with severe Friedreich's ataxia.

Authors:  Giuseppe Arcuria; Christian Marcotulli; Raffaele Amuso; Giuliano Dattilo; Claudio Galasso; Francesco Pierelli; Carlo Casali
Journal:  Neurol Sci       Date:  2020-01-28       Impact factor: 3.307

Review 3.  Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.

Authors:  Renata Santos; Sophie Lefevre; Dominika Sliwa; Alexandra Seguin; Jean-Michel Camadro; Emmanuel Lesuisse
Journal:  Antioxid Redox Signal       Date:  2010-09-01       Impact factor: 8.401

Review 4.  Clinical features of Friedreich ataxia.

Authors:  Martin B Delatycki; Louise A Corben
Journal:  J Child Neurol       Date:  2012-06-29       Impact factor: 1.987

Review 5.  Unanswered questions in Friedreich ataxia.

Authors:  David R Lynch; Eric C Deutsch; Robert B Wilson; Gihan Tennekoon
Journal:  J Child Neurol       Date:  2012-07-25       Impact factor: 1.987

6.  Frataxin gene point mutations in Italian Friedreich ataxia patients.

Authors:  Cinzia Gellera; Barbara Castellotti; Caterina Mariotti; Rossana Mineri; Viviana Seveso; Stefano Didonato; Franco Taroni
Journal:  Neurogenetics       Date:  2007-08-17       Impact factor: 2.660

7.  Friedreich ataxia (FA) associated with diabetes mellitus type 1 and hyperthrophic cardiomyopathy.

Authors:  Zoran Gucev; Velibor Tasic; Aleksandra Jancevska; Nada Popjordanova; Svetlana Koceva; Marija Kuturec; Vesna Sabolic
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

8.  Establishment and Maintenance of Primary Fibroblast Repositories for Rare Diseases-Friedreich's Ataxia Example.

Authors:  Yanjie Li; Urszula Polak; Amanda D Clark; Angela D Bhalla; Yu-Yun Chen; Jixue Li; Jennifer Farmer; Lauren Seyer; David Lynch; Jill S Butler; Marek Napierala
Journal:  Biopreserv Biobank       Date:  2016-03-22       Impact factor: 2.300

Review 9.  Recessive cerebellar and afferent ataxias - clinical challenges and future directions.

Authors:  Marie Beaudin; Mario Manto; Jeremy D Schmahmann; Massimo Pandolfo; Nicolas Dupre
Journal:  Nat Rev Neurol       Date:  2022-03-24       Impact factor: 42.937

10.  Selected missense mutations impair frataxin processing in Friedreich ataxia.

Authors:  Elisia Clark; Jill S Butler; Charles J Isaacs; Marek Napierala; David R Lynch
Journal:  Ann Clin Transl Neurol       Date:  2017-06-29       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.